Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
YCT-529 is a retinoic acid receptor-alpha (RAR-alpha) inhibitor that prevents sperm production by blocking access to vitamin A. It is under phase 1 clinical development for male contraception.
Lead Product(s): YCT-529
Therapeutic Area: Endocrinology Product Name: YCT-529
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quotient Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023